UA78693C2 - Use of eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester for treating heart failure - Google Patents

Use of eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester for treating heart failure Download PDF

Info

Publication number: UA78693C2
Authority: UA; Ukraine
Prior art keywords: heart failure; ethyl ester; item; use according; dha
Prior art date: 2001-01-25

Application number

UA2003087938A

Other languages

English (en)

Ukrainian (uk)

Inventor

Eduardo Lino Stragliotto

Original Assignee

Pharmacia Italia Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-25

Filing date

2002-01-16

Publication date

2007-04-25

2002-01-16 Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa

2007-04-25 Publication of UA78693C2 publication Critical patent/UA78693C2/uk

Links

206010019280 Heart failures Diseases 0.000 title claims abstract description 42
229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 title abstract description 22
SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 title abstract description 22
TYLNXKAVUJJPMU-DNKOKRCQSA-N Docosahexaenoic acid ethyl ester Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(=O)OCC TYLNXKAVUJJPMU-DNKOKRCQSA-N 0.000 title abstract description 6
MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 45
239000003814 drug Substances 0.000 claims abstract description 33
235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 27
235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 26
235000004626 essential fatty acids Nutrition 0.000 claims abstract description 19
239000000203 mixture Substances 0.000 claims abstract description 18
229940124597 therapeutic agent Drugs 0.000 claims abstract description 16
230000002265 prevention Effects 0.000 claims abstract description 14
208000019622 heart disease Diseases 0.000 claims abstract description 12
206010007559 Cardiac failure congestive Diseases 0.000 claims description 22
229940090949 docosahexaenoic acid Drugs 0.000 claims description 22
230000001154 acute effect Effects 0.000 claims description 8
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 8
230000001684 chronic effect Effects 0.000 claims description 8
229960005135 eicosapentaenoic acid Drugs 0.000 claims description 8
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
102000002723 Atrial Natriuretic Factor Human genes 0.000 claims description 6
101800001288 Atrial natriuretic factor Proteins 0.000 claims description 6
101800001890 Atrial natriuretic peptide Proteins 0.000 claims description 6
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 claims description 6
239000003112 inhibitor Substances 0.000 claims description 6
239000005541 ACE inhibitor Substances 0.000 claims description 5
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 5
238000002648 combination therapy Methods 0.000 claims description 5
125000004494 ethyl ester group Chemical group 0.000 claims description 5
LTMHDMANZUZIPE-UHFFFAOYSA-N 3-[3-[5-[5-(4,5-dihydroxy-6-methyloxan-2-yl)oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2h-furan-5-one Chemical compound C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 4
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 4
WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 claims description 4
239000002876 beta blocker Substances 0.000 claims description 4
229940097320 beta blocking agent Drugs 0.000 claims description 4
229960000648 digitoxin Drugs 0.000 claims description 4
WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 claims description 4
239000002934 diuretic Substances 0.000 claims description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 4
WDKXLLJDNUBYCY-UHFFFAOYSA-N ibopamine Chemical compound CNCCC1=CC=C(OC(=O)C(C)C)C(OC(=O)C(C)C)=C1 WDKXLLJDNUBYCY-UHFFFAOYSA-N 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
229960002237 metoprolol Drugs 0.000 claims description 4
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 4
239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 4
229940124549 vasodilator Drugs 0.000 claims description 4
239000003071 vasodilator agent Substances 0.000 claims description 4
DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 3
GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 3
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 3
108010061435 Enalapril Proteins 0.000 claims description 3
229960003304 acetyldigoxin Drugs 0.000 claims description 3
HWKJSYYYURVNQU-DXJNJSHLSA-N acetyldigoxin Chemical compound C1[C@H](OC(C)=O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O HWKJSYYYURVNQU-DXJNJSHLSA-N 0.000 claims description 3
MGVYFNHJWXJYBE-UHFFFAOYSA-N alpha-Acetyl-digoxin Natural products CC1OC(CC(O)C1O)OC2C(O)CC(OC3C(C)OC(CC3OC(=O)C)OC4CCC5(C)C(CCC6C5CCC7(C)C(C(O)CC67O)C8=CC(=O)OC8)C4)OC2C MGVYFNHJWXJYBE-UHFFFAOYSA-N 0.000 claims description 3
229960002105 amrinone Drugs 0.000 claims description 3
RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 claims description 3
229960000830 captopril Drugs 0.000 claims description 3
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 3
229960004195 carvedilol Drugs 0.000 claims description 3
NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
229960005025 cilazapril Drugs 0.000 claims description 3
HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 claims description 3
229960005156 digoxin Drugs 0.000 claims description 3
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 3
208000035475 disorder Diseases 0.000 claims description 3
KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 3
229960000873 enalapril Drugs 0.000 claims description 3
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 3
229960000972 enoximone Drugs 0.000 claims description 3
ZJKNESGOIKRXQY-UHFFFAOYSA-N enoximone Chemical compound C1=CC(SC)=CC=C1C(=O)C1=C(C)NC(=O)N1 ZJKNESGOIKRXQY-UHFFFAOYSA-N 0.000 claims description 3
229960003883 furosemide Drugs 0.000 claims description 3
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 3
229960002474 hydralazine Drugs 0.000 claims description 3
229960002003 hydrochlorothiazide Drugs 0.000 claims description 3
229960000201 isosorbide dinitrate Drugs 0.000 claims description 3
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims description 3
208000010125 myocardial infarction Diseases 0.000 claims description 3
229960002164 pimobendan Drugs 0.000 claims description 3
GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 claims description 3
-1 visoprolol Chemical compound 0.000 claims description 3
LPUDGHQMOAHMMF-JBACZVJFSA-N (2s)-2-[[[(2s)-6-amino-2-(methanesulfonamido)hexanoyl]amino]methyl]-3-[1-[[(1s)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]cyclopentyl]propanoic acid Chemical compound N([C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)C1(C[C@@H](CNC(=O)[C@H](CCCCN)NS(=O)(=O)C)C(O)=O)CCCC1 LPUDGHQMOAHMMF-JBACZVJFSA-N 0.000 claims description 2
239000002083 C09CA01 - Losartan Substances 0.000 claims description 2
239000004072 C09CA03 - Valsartan Substances 0.000 claims description 2
239000002053 C09CA06 - Candesartan Substances 0.000 claims description 2
229960000932 candesartan Drugs 0.000 claims description 2
SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims description 2
150000001875 compounds Chemical class 0.000 claims description 2
229960003638 dopamine Drugs 0.000 claims description 2
229960004370 ibopamine Drugs 0.000 claims description 2
229940124975 inotropic drug Drugs 0.000 claims description 2
229960004773 losartan Drugs 0.000 claims description 2
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 claims description 2
229950000973 omapatrilat Drugs 0.000 claims description 2
229950001780 sampatrilat Drugs 0.000 claims description 2
229960004699 valsartan Drugs 0.000 claims description 2
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 2
102000015427 Angiotensins Human genes 0.000 claims 1
108010064733 Angiotensins Proteins 0.000 claims 1
102000004190 Enzymes Human genes 0.000 claims 1
108090000790 Enzymes Proteins 0.000 claims 1
229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
230000003130 cardiopathic effect Effects 0.000 claims 1
230000001882 diuretic effect Effects 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
238000000034 method Methods 0.000 abstract description 10
230000001225 therapeutic effect Effects 0.000 abstract description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
229940079593 drug Drugs 0.000 description 8
239000002775 capsule Substances 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 5
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 4
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 4
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 4
239000002253 acid Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 3
230000006866 deterioration Effects 0.000 description 3
229940030606 diuretics Drugs 0.000 description 3
230000004064 dysfunction Effects 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
238000005086 pumping Methods 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
229940087168 alpha tocopherol Drugs 0.000 description 2
229960002781 bisoprolol Drugs 0.000 description 2
VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
229940082657 digitalis glycosides Drugs 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
239000004041 inotropic agent Substances 0.000 description 2
229960003746 metildigoxin Drugs 0.000 description 2
IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 description 2
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229960000984 tocofersolan Drugs 0.000 description 2
239000002076 α-tocopherol Substances 0.000 description 2
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
HPMZBILYSWLILX-UMDUKNJSSA-N 3'''-O-acetyldigitoxin Chemical compound C1[C@H](OC(C)=O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O HPMZBILYSWLILX-UMDUKNJSSA-N 0.000 description 1
HPMZBILYSWLILX-UHFFFAOYSA-N Acetyl-digitoxine Natural products C1C(OC(C)=O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O HPMZBILYSWLILX-UHFFFAOYSA-N 0.000 description 1
206010003178 Arterial thrombosis Diseases 0.000 description 1
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
206010007558 Cardiac failure chronic Diseases 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 1
NENBAISIHCWPKP-UHFFFAOYSA-N Clofenamide Chemical compound NS(=O)(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NENBAISIHCWPKP-UHFFFAOYSA-N 0.000 description 1
241000208011 Digitalis Species 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
208000031309 Hypertrophic Familial Cardiomyopathy Diseases 0.000 description 1
JAYAGJDXJIDEKI-UHFFFAOYSA-N Lanatoside C Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)C(O)C4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(OC(C)=O)C1OC1OC(CO)C(O)C(O)C1O JAYAGJDXJIDEKI-UHFFFAOYSA-N 0.000 description 1
JAYAGJDXJIDEKI-PTGWOZRBSA-N Lanatoside C Chemical compound O([C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JAYAGJDXJIDEKI-PTGWOZRBSA-N 0.000 description 1
108010007859 Lisinopril Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000208125 Nicotiana Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
229960003635 acetyldigitoxin Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
229960002576 amiloride Drugs 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
230000007214 atherothrombosis Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000005242 cardiac chamber Anatomy 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
229960002320 celiprolol Drugs 0.000 description 1
229960002155 chlorothiazide Drugs 0.000 description 1
229960001523 chlortalidone Drugs 0.000 description 1
229960002883 clofenamide Drugs 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
229960005227 delapril Drugs 0.000 description 1
WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
229940005501 dopaminergic agent Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
229960003199 etacrynic acid Drugs 0.000 description 1
230000004090 etiopathogenesis Effects 0.000 description 1
229960004514 etozolin Drugs 0.000 description 1
ZCKKHYXUQFTBIK-KTKRTIGZSA-N etozoline Chemical compound O=C1N(C)C(=C/C(=O)OCC)/SC1N1CCCCC1 ZCKKHYXUQFTBIK-KTKRTIGZSA-N 0.000 description 1
201000006692 familial hypertrophic cardiomyopathy Diseases 0.000 description 1
235000021323 fish oil Nutrition 0.000 description 1
229960002490 fosinopril Drugs 0.000 description 1
230000005802 health problem Effects 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
231100000171 higher toxicity Toxicity 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
229960002614 lanatoside c Drugs 0.000 description 1
229960002394 lisinopril Drugs 0.000 description 1
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960003574 milrinone Drugs 0.000 description 1
PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
230000002644 neurohormonal effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
229960002582 perindopril Drugs 0.000 description 1
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
230000036581 peripheral resistance Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
229960001749 practolol Drugs 0.000 description 1
DURULFYMVIFBIR-UHFFFAOYSA-N practolol Chemical compound CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1 DURULFYMVIFBIR-UHFFFAOYSA-N 0.000 description 1
WXSLOYPZKHFWII-UHFFFAOYSA-N propyl 4-hydroxybenzoate;sodium Chemical compound [Na].CCCOC(=O)C1=CC=C(O)C=C1 WXSLOYPZKHFWII-UHFFFAOYSA-N 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
229960001455 quinapril Drugs 0.000 description 1
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
229960003401 ramipril Drugs 0.000 description 1
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
230000008085 renal dysfunction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
ZLVSYODPTJZFMK-UHFFFAOYSA-M sodium 4-hydroxybenzoate Chemical compound [Na+].OC1=CC=C(C([O-])=O)C=C1 ZLVSYODPTJZFMK-UHFFFAOYSA-M 0.000 description 1
235000010230 sodium propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004404 sodium propyl p-hydroxybenzoate Substances 0.000 description 1
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
229960002256 spironolactone Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229960005461 torasemide Drugs 0.000 description 1
229960002051 trandolapril Drugs 0.000 description 1
229960001288 triamterene Drugs 0.000 description 1
229960004813 trichlormethiazide Drugs 0.000 description 1
LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
229950005577 vesnarinone Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Organic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UA2003087938A 2001-01-25 2002-01-16 Use of eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester for treating heart failure UA78693C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT2001MI000129A ITMI20010129A1 (it)	2001-01-25	2001-01-25	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
PCT/EP2002/000507 WO2002058793A1 (en)	2001-01-25	2002-01-16	Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy

Publications (1)

Publication Number	Publication Date
UA78693C2 true UA78693C2 (en)	2007-04-25

Family

ID=11446587

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2003087938A UA78693C2 (en)	2001-01-25	2002-01-16	Use of eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester for treating heart failure

Country Status (21)

Country	Link
US (3)	US20040077723A1 (xx)
EP (2)	EP2258447A3 (xx)
JP (1)	JP2004517148A (xx)
AU (1)	AU2002225026B2 (xx)
BG (1)	BG108071A (xx)
CA (1)	CA2433762A1 (xx)
CZ (1)	CZ20031947A3 (xx)
EA (1)	EA200300830A1 (xx)
EE (1)	EE05320B1 (xx)
HR (1)	HRP20030561A2 (xx)
HU (1)	HUP0303019A2 (xx)
IS (1)	IS6862A (xx)
IT (1)	ITMI20010129A1 (xx)
MX (1)	MX282405B (xx)
NO (1)	NO20033304D0 (xx)
NZ (1)	NZ526609A (xx)
PL (1)	PL363269A1 (xx)
SK (1)	SK8332003A3 (xx)
UA (1)	UA78693C2 (xx)
WO (1)	WO2002058793A1 (xx)
YU (1)	YU59303A (xx)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9901809D0 (en) *	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
ITMI20010129A1 (it) *	2001-01-25	2002-07-25	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
ITMI20012384A1 (it)	2001-11-12	2003-05-12	Quatex Nv	Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
ITMI20020269A1 (it) *	2002-02-12	2003-08-12	Victorix Assets Ltd	Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
EP1564278B1 (en) *	2002-11-22	2018-01-10	Nippon Suisan Kaisha, Ltd.	Composition containing organic substance having double bond with improved oxidation stability
ITMI20022511A1 (it) *	2002-11-26	2004-05-27	Victorix Assets Ltd	Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
CN102391222B (zh) *	2003-04-07	2015-10-21	法莫西克立克斯公司	作为治疗剂的异羟肟酸酯
WO2004091603A1 (fr) *	2003-04-07	2004-10-28	Clinigenetics	Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
SE0303513D0 (sv) *	2003-12-19	2003-12-19	Pronova Biocare As	Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
CA2568640C (en)	2004-06-04	2011-08-09	Teva Pharmaceutical Industries Ltd.	Pharmaceutical composition containing irbesartan
US20090075956A1 (en) *	2005-04-07	2009-03-19	Nitromed, Inc.	Genetic Risk Assessment in Heart Failure: Impact of the Genetic Variation of NOS3
FR2902659A1 (fr) *	2006-06-23	2007-12-28	Pierre Fabre Medicament Sa	Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
US20090011012A1 (en) *	2007-07-06	2009-01-08	Baum Seth J	Fatty acid compositions and methods of use
US9468668B2 (en)	2011-08-11	2016-10-18	Allergy Research Group, Llc	Flavored chewable lipid supplements for maintaining health and the treatment of acute and chronic disorders
US8877239B2 (en)	2010-08-12	2014-11-04	Nutritional Therapeutics, Inc.	Lipid supplements for maintaining health and treatment of acute and chronic disorders
US8343753B2 (en)	2007-11-01	2013-01-01	Wake Forest University School Of Medicine	Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2010015335A1 (en)	2008-08-07	2010-02-11	Spa Societa' Prodotti Antibiotici S.P.A.	Long-term treatment of symptomatic heart failure
WO2010018856A1 (ja) *	2008-08-13	2010-02-18	持田製薬株式会社	カンナビノイド受容体関連疾患の予防／改善または治療剤
PL2334295T3 (pl)	2008-09-02	2017-12-29	Amarin Pharmaceuticals Ltd	Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania
SI2596786T1 (sl)	2009-02-10	2020-03-31	Amarin Pharmaceuticals Ireland Limited,	Uporaba etilestra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije
US9925162B2 (en)	2009-04-09	2018-03-27	The Regents Of The University Of Colorado	Methods and compositions for inducing physiological hypertrophy
NZ720946A (en)	2009-04-29	2017-09-29	Amarin Pharmaceuticals Ie Ltd	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN104856985B (zh)	2009-04-29	2019-01-04	阿马里纳制药爱尔兰有限公司	稳定的药物组合物和使用其的方法
CA3026006C (en)	2009-06-15	2021-09-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
WO2011038122A1 (en)	2009-09-23	2011-03-31	Amarin Corporation Plc	Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
MX337315B (es) *	2010-03-04	2016-02-25	Amarin Pharma Inc	Composiciones y metodos para tratar y/o prevenir enfermedad cardiovascular.
US20140127289A1 (en)	2010-11-29	2014-05-08	Armarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
CA2826663A1 (en) *	2011-02-07	2012-08-16	Mochida Pharmaceutical Co., Ltd.	Therapeutic agent for diastolic congestive heart failure
US9119826B2 (en)	2011-02-16	2015-09-01	Pivotal Therapeutics, Inc.	Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en)	2011-02-16	2015-02-10	Pivotal Therapeutics Inc.	Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8715648B2 (en)	2011-02-16	2014-05-06	Pivotal Therapeutics Inc.	Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en)	2011-02-16	2015-02-10	Pivotal Therapeutics Inc.	Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US11253531B2 (en)	2011-08-11	2022-02-22	Nutritional Therapeutics, Inc.	Lipid supplements for reducing nerve action potentials
US10117885B2 (en)	2011-08-11	2018-11-06	Allergy Research Group, Llc	Chewable lipid supplements for treating pain and fibromyalgia
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US20130131170A1 (en)	2011-11-07	2013-05-23	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
JP6307442B2 (ja)	2012-01-06	2018-04-04	アマリンファーマシューティカルスアイルランドリミテッド	対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
RS67161B1 (sr)	2012-06-29	2025-09-30	Amarin Pharmaceuticals Ie Ltd	Etil estar eikozapentaenske kiseline za upotrebu u smanjenju rizika od nesmrtonosnog šloga kod pacijenta na terapiji statinima
WO2014074552A2 (en)	2012-11-06	2014-05-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
KR20160063419A (ko)	2013-01-10	2016-06-03	뉴트리셔널 테라퓨틱스, 인크.	건강 유지 및 급성 및 만성 장애의 치료를 위한 지질 보조제를 함유하는 식용 웨이퍼
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
WO2015195662A1 (en)	2014-06-16	2015-12-23	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en)	2017-05-19	2018-11-22	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA50490A (fr)	2018-09-24	2020-09-02	Amarin Pharmaceuticals Ie Ltd	Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
BR112022009189A2 (pt)	2019-11-12	2022-07-26	Amarin Pharmaceuticals Ie Ltd	Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
AU2022263358A1 (en)	2021-04-21	2023-11-30	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5735512A (en)	1980-06-27	1982-02-26	Nippon Oil & Fats Co Ltd	Preventive and remedy for thrombosis
NO157302C (no)	1985-12-19	1988-02-24	Norsk Hydro As	Fremgangsmaate for fremstilling av et fiskeoljekonsentrat.
US4920098A (en) *	1986-09-17	1990-04-24	Baxter International Inc.	Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
IT1205043B (it)	1987-05-28	1989-03-10	Innova Di Ridolfi Flora & C S	Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
GB2218984B (en) *	1988-05-27	1992-09-23	Renafield Limited	Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
DD273852B3 (de)	1988-07-07	1993-01-21	Zentralinstitut Fuer Ernaehrun	Verfahren zur gewinnung und aufkonzentrierung polyenfettsaeurereicher lipide
GB8819110D0 (en)	1988-08-11	1988-09-14	Norsk Hydro As	Antihypertensive drug & method for production
US6140304A (en)	1988-09-28	2000-10-31	Eicotech Corporation	Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia
JP3103588B2 (ja)	1990-11-16	2000-10-30	持田製薬株式会社	リポプロテイン（ａ）低下剤
US5324323A (en) *	1992-09-09	1994-06-28	Telectronics Pacing Systems, Inc.	Multiple channel cardiosynchronous myoplasty apparatus
US5208236A (en) *	1992-09-23	1993-05-04	Schering Corporation	N-(acylaminomethyl)glutaryl amino acids and use
WO1994013642A1 (de) *	1992-12-11	1994-06-23	Ciba-Geigy Ag	Substituierte benzazepinone
CN1082909A (zh)	1993-01-03	1994-03-02	潘玉珍	精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂
JPH06263634A (ja)	1993-03-10	1994-09-20	Sagami Chem Res Center	カルシウム拮抗薬
JPH07118229A (ja) *	1993-10-19	1995-05-09	Fujisawa Pharmaceut Co Ltd	尿素誘導体およびその製造法
US5760081A (en) *	1994-05-10	1998-06-02	The General Hospital Corporation	Omega 3 fatty acids in the prevention of ventricular fibrillation
JPH0812581A (ja) *	1994-06-30	1996-01-16	Fujirebio Inc	虚血性心疾患治療剤
JPH0853350A (ja)	1994-08-11	1996-02-27	Sagami Chem Res Center	抗肺水腫薬
IT1274734B (it) *	1994-08-25	1997-07-24	Prospa Bv	Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
JPH08151334A (ja)	1994-11-25	1996-06-11	Sagami Chem Res Center	リポソームおよびその製剤
GB9506837D0 (en)	1995-04-03	1995-05-24	Scotia Holdings Plc	Triglycerides
MY118354A (en)	1995-05-01	2004-10-30	Scarista Ltd	1,3-propane diol derivatives as bioactive compounds
ES2200023T3 (es)	1995-08-17	2004-03-01	F. Hoffmann-La Roche Ag	Procedimiento cromatografico.
IT1277953B1 (it)	1995-12-21	1997-11-12	Sigma Tau Ind Farmaceuti	Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
US6333447B1 (en) *	1996-03-29	2001-12-25	The General Hospital Corporation	Transgenic model of heart failure
US5861399A (en) *	1996-07-17	1999-01-19	Heart Care Partners	Methods and compositions for the rapid and enduring relief of inadequate myocardial function
EA199900261A1 (ru) *	1996-09-05	1999-10-28	Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния	Генная терапия застойной сердечной недостаточности
WO1998057628A1 (fr) *	1997-06-16	1998-12-23	Nippon Suisan Kaisha, Ltd.	Composition capable de supprimer le facteur de risque pendant l'exercice
PT2322174E (pt) *	1998-07-10	2015-10-27	Novartis Pharma Gmbh	Utilização combinada de valsartan e bloqueadores do canal de cálcio com objetivos terapêuticos
IT1308613B1 (it) *	1999-02-17	2002-01-09	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
GB9916536D0 (en)	1999-07-14	1999-09-15	Scarista Limited	Nutritional or pharmaceutical compositions
ES2159257B1 (es)	1999-11-19	2002-04-16	Kd Iqa S L	Nuevo procedimiento de preparacion del ester etilico del acido eicosa pentaenoico.
CA2291959A1 (en)	1999-12-08	2001-06-08	Alex P. Korn	A nutriceutical composition of l-carnitine, ubiquinone, n-3 polyunsaturated fatty acids and vitamins specifically formulated at pharmacological doses for the amelioration of the risk factors and symptoms of atherosclerosis-related illnesses
US8753675B1 (en)	2000-01-20	2014-06-17	Raj K. Chopra	Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
JP4932116B2 (ja)	2000-02-16	2012-05-16	ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド	アスピリン誘発脂質メディエータ
EP1130027A1 (de) *	2000-02-29	2001-09-05	Aventis Pharma Deutschland GmbH	Memno-Peptide, Verfahren zu ihrer Herstellung und Verwendung derselben
JP4139544B2 (ja)	2000-03-06	2008-08-27	花王株式会社	血糖値低下剤
CA2304906A1 (en)	2000-04-07	2001-10-07	1411198 Ontario Limited	13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
DE60022987T2 (de)	2000-05-22	2006-10-19	Pro Aparts - Investimentos E Consultoria Lda., Funchal	Fettsäurezusammensetzung, die wenigstens 80 Gew.-% EPA und DHA enthält
GB0016045D0 (en)	2000-06-29	2000-08-23	Laxdale Limited	Therapeutic combinations of fatty acids
DE10056351A1 (de)	2000-11-14	2002-05-29	Weylandt Karsten Henrich	Pharmazeutisches Präparat
ITMI20010129A1 (it) *	2001-01-25	2002-07-25	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco

2001
- 2001-01-25 IT IT2001MI000129A patent/ITMI20010129A1/it unknown
2002
- 2002-01-16 CA CA002433762A patent/CA2433762A1/en not_active Abandoned
- 2002-01-16 UA UA2003087938A patent/UA78693C2/uk unknown
- 2002-01-16 NZ NZ526609A patent/NZ526609A/en not_active IP Right Cessation
- 2002-01-16 AU AU2002225026A patent/AU2002225026B2/en not_active Ceased
- 2002-01-16 JP JP2002559123A patent/JP2004517148A/ja active Pending
- 2002-01-16 EE EEP200300297A patent/EE05320B1/xx not_active IP Right Cessation
- 2002-01-16 MX MXPA03006480 patent/MX282405B/es active IP Right Grant
- 2002-01-16 SK SK833-2003A patent/SK8332003A3/sk not_active Application Discontinuation
- 2002-01-16 CZ CZ20031947A patent/CZ20031947A3/cs unknown
- 2002-01-16 WO PCT/EP2002/000507 patent/WO2002058793A1/en not_active Ceased
- 2002-01-16 EP EP10183221A patent/EP2258447A3/en not_active Withdrawn
- 2002-01-16 US US10/451,623 patent/US20040077723A1/en not_active Abandoned
- 2002-01-16 YU YU59303A patent/YU59303A/sh unknown
- 2002-01-16 HU HU0303019A patent/HUP0303019A2/hu unknown
- 2002-01-16 PL PL02363269A patent/PL363269A1/xx not_active Application Discontinuation
- 2002-01-16 HR HR20030561A patent/HRP20030561A2/hr not_active Application Discontinuation
- 2002-01-16 EP EP02715455A patent/EP1365841A1/en not_active Ceased
- 2002-01-16 EA EA200300830A patent/EA200300830A1/ru unknown
2003
- 2003-06-27 IS IS6862A patent/IS6862A/is unknown
- 2003-07-22 NO NO20033304A patent/NO20033304D0/no not_active Application Discontinuation
- 2003-08-07 BG BG108071A patent/BG108071A/bg unknown
2006
- 2006-01-17 US US11/333,387 patent/US7439267B2/en not_active Expired - Fee Related
2008
- 2008-09-09 US US12/207,068 patent/US20090005327A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PL363269A1 (en)	2004-11-15
BG108071A (bg)	2005-04-30
HUP0303019A2 (hu)	2003-12-29
HRP20030561A2 (en)	2005-06-30
CA2433762A1 (en)	2002-08-01
MX282405B (es)	2010-12-21
US20040077723A1 (en)	2004-04-22
EA200300830A1 (ru)	2003-12-25
EE200300297A (et)	2003-10-15
YU59303A (sh)	2006-08-17
EE05320B1 (et)	2010-08-16
MXPA03006480A (es)	2003-09-22
US7439267B2 (en)	2008-10-21
EP2258447A2 (en)	2010-12-08
EP1365841A1 (en)	2003-12-03
US20090005327A1 (en)	2009-01-01
NO20033304L (no)	2003-07-22
IS6862A (is)	2003-06-27
US20060205814A1 (en)	2006-09-14
NZ526609A (en)	2005-10-28
WO2002058793A1 (en)	2002-08-01
ITMI20010129A1 (it)	2002-07-25
AU2002225026B2 (en)	2007-09-13
CZ20031947A3 (cs)	2003-12-17
NO20033304D0 (no)	2003-07-22
SK8332003A3 (en)	2003-11-04
JP2004517148A (ja)	2004-06-10
EP2258447A3 (en)	2012-07-25

Publication	Publication Date	Title
UA78693C2 (en)	2007-04-25	Use of eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester for treating heart failure
AU2002225026A1 (en)	2003-02-06	Essential N-3 fatty acids in cardiac insufficiency and heart failure therapy
JP5441287B2 (ja)	2014-03-12	心血管事象を予防するための必須脂肪酸
US7887852B2 (en)	2011-02-15	Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
KR20210158422A (ko)	2021-12-30	ω3 지방산의 자기 유화 조성물
WO2004069238A1 (ja)	2004-08-19	くも膜下出血の予後改善剤
WO1995017889A1 (en)	1995-07-06	Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis
KR20010040776A (ko)	2001-05-15	염증 상태의 치료방법 및 이를 위한 조성물
RS59303B1 (sr)	2019-10-31	Spojnica
CA2346647C (en)	2003-03-11	Treatment of dyspepsia
RU2387448C2 (ru)	2010-04-27	Незаменимые жирные кислоты, предназначенные для предупреждения и/или лечения депрессии у пациентов, страдающих коронарной болезнью сердца или болезнью коронарной артерии
US20080160001A1 (en)	2008-07-03	Antihypercholesterolemic Formulation with Less Side-Effects
JPH07233062A (ja)	1995-09-05	人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物
JP2025510391A (ja)	2025-04-14	ビタミンｋ２に基づく高齢者の生命品質を向上する薬物組成物、調製方法及び応用
JP2007532605A5 (xx)	2012-01-26
CN108186670A (zh)	2018-06-22	一种用于治疗肥胖的药物组合物及其制备方法
MXPA01008213A (en)	2002-06-05	Essential fatty acids in the prevention of cardiovascular events